Based on the aggregated intelligence of 180,000-plus investors participating in Motley Fool CAPS, the Fool's free investing community, health care giant Abbott Laboratories (NYSE:ABT) has earned a coveted five-star ranking.

With that in mind, let's take a closer look at Abbott and see what CAPS investors are saying about the stock right now.

Abbott facts

Headquarters (founded)

Abbott Park, Ill. (1888)

Market Cap

$102.5 billion

Industry

Drug manufacturers

Trailing-12-Month Revenue

$39.4 billion

Management

Chairman/CEO Miles White (since 1999)
CFO Thomas Freyman (since 2001)

Return on Equity (average, past 3 years)

22.3%

Cash/Debt

$11.5 billion / $16.3 billion

Dividend Yield

3.1%

Competitors

Johnson & Johnson (NYSE:JNJ)Merck (NYSE:MRK)Sanofi (NYSE:SNY)

Sources: S&P Capital IQ and Motley Fool CAPS.

On CAPS, 96% of the 2,643 members who have rated Abbott believe the stock will outperform the S&P 500 going forward.

Just yesterday, one of those Fools, EVplusEV, brought a couple of catalysts to our community's attention:

Catalyst #1: [Abbott] presenting at the American Association for the Study of Liver Diseases ... look for positive reports on its Hep C program. Catalyst #2: Splitting into two companies sometime after the first of the year; one pharma and one medical technology. Stock is down over 9% from the highs and with these catalysts, I'm in this on a trade with a target of $71 per share.

If you want to retire rich, you need to put together the best portfolio you can. Owning exceptional stocks is a surefire way to secure your financial future. Of course, despite its five-star rating, Abbott may not be your top choice.

If that's the case, we've compiled a special free report for investors called "Secure Your Future With 9 Rock-Solid Dividend Stocks," which uncovers several other juicy income opportunities. The report is 100% free, but it won't be around forever, so click here to access it now.

Want to see how well (or not so well) the stocks in this series are performing? Follow the TrackPoisedTo CAPS account.

Fool contributor Brian Pacampara has no positions in the stocks mentioned above. The Motley Fool owns shares of Johnson & Johnson. Motley Fool newsletter services recommend Johnson & Johnson. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.